Current Cardiovascular Risk Reports

, Volume 7, Issue 6, pp 417–422 | Cite as

Metformin in Diabetic Patients with Heart Failure: Safe and Effective

  • Ijeoma Ananaba Ekeruo
  • Amirreza Solhpour
  • Heinrich Taegtmeyer
Invited Commentary

Abstract

Management of diabetic patients with heart failure is a complex endeavor. The initial reluctance to use metformin in these patients has given way to a broader acceptance after clinical trials and meta-analyses have revealed that some of the insulin-sensitizing agents lead to adverse cardiovascular events. We have proposed that an increase of substrate uptake by the insulin-resistant heart is detrimental because the heart is already flooded with fuel. In light of this evidence, metformin offers a unique safety profile in the patient with diabetes and heart failure. Our article expands on the use of metformin in patients with heart failure. We propose that the drug targets both the source as well as the destination (in this case the heart) of excess fuel. We consider treatment of diabetic heart failure patients with metformin both safe and effective.

Keywords

Type 2 diabetes mellitus Heart failure Anti-diabetic drugs 

Notes

Acknowledgments

We thank Roxy A. Tate for expert editorial assistance. Work in H.T.’s lab is supported by the NHLBI (R01-HL061483 and R01-HL073162.)

Compliance with Ethics Guidelines

Conflict of Interest

Heinrich Taegtmeyer, Ijeoma Ananaba Ekeruo and Amirreza Solhpour declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any original data with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1c criteria in the U.S. Population in 1988-2006. Diabetes Care. 2010;33(3):562–8.PubMedCrossRefGoogle Scholar
  2. 2.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46.CrossRefGoogle Scholar
  3. 3.
    Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Nissen SE. The rise and fall of rosiglitazone. Eur Heart J. 2010;31(7):773–6.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16(3):200–6. A retrospective cohort study that included 401 patients with DM and severe heart failure followed between 1994 and 2008. Although there was a trend to improvement of outcomes in the patients on metformin, the results were not statistically significant.PubMedCrossRefGoogle Scholar
  6. 6.
    Khalaf KI, Taegtmeyer H. After Avandia: the use of Antidiabetic drugs in patients with heart failure. Tex Heart Inst J. 2012;39(2):174–8.PubMedGoogle Scholar
  7. 7.
    Purcell IF, Poole-Wilson PA. Heart failure: why and how to define it? Eur J Heart Fail. 1999;1(1):7–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care. 2003;26(10):2791–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103(22):2668–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105(14):1727–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Factor SM, Borczuk A, Charron MJ, Fein FS, van Hoeven KH, Sonnenblick EH. Myocardial alterations in diabetes and hypertension. Diabetes Res Clin Pract. 1996;31(Suppl):S133–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101(19):2271–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Hardin NJ. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis. 1996;7(2):99–108.PubMedCrossRefGoogle Scholar
  16. 16.
    Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998; 40(2):239–47.Google Scholar
  17. 17.
    MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;29(10):1224–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2c and myocyte enhancer factor 2c-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation. 2002;106(4):407–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Young ME, Yan J, Razeghi P, Cooksey RC, Guthrie PH, Stepkowski SM, McClain DA, Tian R, Taegtmeyer H. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio. 2007;1:1251–262.Google Scholar
  20. 20.
    Benbow A, Stewart M, Yeoman G. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ. 2001;322(7280):236.PubMedCrossRefGoogle Scholar
  21. 21.
    Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.PubMedCrossRefGoogle Scholar
  22. 22.
    Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97.PubMedCrossRefGoogle Scholar
  23. 23.
    Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–80.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2010;4(1):53–8. A multicenter retrospective cohort study that studied metformin use in ambulatory patients with DM and CHF. Here, metformin use was associated with a significantly lower rate of mortality. Surprisingly, in this study the effect of the use of metformin on the rate of hospitalizations was minimal.PubMedCrossRefGoogle Scholar
  25. 25.
    Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294(3):334–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.PubMedCrossRefGoogle Scholar
  27. 27.
    •• Khalaf KI, Taegtmeyer H. Insulin sensitizers and heart failure: an engine flooded with fuel. Curr Hypertens Rep. 2010;12(6):399–401. A concise review of the literature, drawing special attention to the present difficulty in treating patients.PubMedCrossRefGoogle Scholar
  28. 28.
    Brunton L, Chabner B, Knollman B. Goodman and Gillman's the pharmacological basis of therapeutics. New York: McGraw Hill Professional Publications; 2010.Google Scholar
  29. 29.
    Hardie G. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013;62(7):2164–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.Google Scholar
  32. 32.
    Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2):H459–68.PubMedCrossRefGoogle Scholar
  33. 33.
    Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 2009;119(19):2568–77.PubMedCrossRefGoogle Scholar
  34. 34.
    • Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-SMAD3 signalling pathway. Cardiovasc Res. 2010;87(3):504–13. A rodent animal study investigating cardioprotective effects of metformin. Specifically the role of metformin in decreasing cardiac fibrosis was investigated and a pathway was proposed.PubMedCrossRefGoogle Scholar
  35. 35.
    Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104(3):403–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010;120(5):1506–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57(3):696–705.PubMedCrossRefGoogle Scholar
  38. 38.
    Russell 3rd RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114(4):495–503.PubMedGoogle Scholar
  39. 39.
    Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a risk for cardioprotection. Heart Fail Rev. 2007;12(3–4):217–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Hausenloy DJ. Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science). Curr Pharm Des. 2013;19(25):4544–63.PubMedCrossRefGoogle Scholar
  41. 41.
    Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100.PubMedCrossRefGoogle Scholar
  42. 42.
    Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: The loss of protective akt signalling. Cardiovasc Res. 2013;99(4):694–704.Google Scholar
  44. 44.
    •• Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW, et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc. 2013;2(3):e004796. This study shows for the fist time that an intermediary metabolie (glucose 6-phosphate, G6P) regulates mTOR, the endoplasmic reticulum (ER) stress response and contratile efficiency in animal models and the failing human heart. Metformin improves contractile function by reducing G6P levels and ER stress.PubMedCrossRefGoogle Scholar
  45. 45.
    Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia. 1978;14(2):75–87.PubMedCrossRefGoogle Scholar
  46. 46.
    Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol. 2002;15(4):398–402.PubMedGoogle Scholar
  47. 47.
    Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with niddm. Diabetes Care. 1997;20(6):925–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338(4):265–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402.PubMedCrossRefGoogle Scholar
  50. 50.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; (4):CD002967.Google Scholar
  51. 51.
    • Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the shhf rat model. Diabetes. 2012;61(4):944–53. Longitudinal animal study where rats with hypertensive heart disease were treated with metformin and rosiglitazone. Metformin was associated with improved cardiac outcomes and decreased progression to heart failure.PubMedCrossRefGoogle Scholar
  52. 52.
    Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail. 2012;14(11):1303–10.PubMedCrossRefGoogle Scholar
  53. 53.
    Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102(20 Suppl 4):IV14–23.PubMedGoogle Scholar
  54. 54.
    Algahim MF, Sen S, Taegtmeyer H. Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol. 2012;302(8):H1539–45.PubMedCrossRefGoogle Scholar
  55. 55.
    Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. J Am Coll Cardiol HF. 2013;1(2):93–102.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ijeoma Ananaba Ekeruo
    • 1
  • Amirreza Solhpour
    • 1
  • Heinrich Taegtmeyer
    • 1
  1. 1.Division of Cardiovascular MedicineThe University of Texas Medical School at HoustonHoustonUSA

Personalised recommendations